English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The systemic amyloidoses are a group of uncommon diseases in which the common factor is infiltration of one or more organs with a noncellular, extracellular proteinaceous material with specific light microscopic staining characteristics [1]. Significant advances in treatment have been made over the past decade, particularly in AL amyloidosis in which the precursor protein is derived from immunoglobulin light chain fragments [2]. Transthyretin (TTR)-derived amyloidosis has also been the subject of intensive investigation, and several new therapeutic approaches have completed, or are approaching, preliminary clinical testing [3–7]. Refinements in immunohistochemical and proteomic techniques have permitted precise definition of the amyloid type, a prerequisite for initiating appropriate (and avoiding inappropriate) therapies [8]. In 2005, the Bologna group published data from 25 patients with amyloidosis (17 of whom had TTR-related amyloidosis) suggesting the bone-scanning agent Tc3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) was preferentially taken up by the heart in patients with TTR amyloidosis, whereas it showed no uptake in AL amyloidosis or in controls without the disease [9]. This appeared to be isotope specific, as Tc-methylene diphosphonate (MDP) showed no uptake in 11 patients who showed distinct myocardial uptake with Tc-DPD. The authors have now expanded their original observations and, while confirming the tracer is avidly taken up in the TTR amyloid patients, they now also describe a mild to moderate uptake in one third of AL patients, thereby reducing the specificity of the test for TTR amyloidosis alone but still rendering it an interesting and informative technique [10]. Uptake of technetium-based bone imaging traces by the heart in cardiac amyloidosis is not a newly described phenomenon. As pointed out by Rapezzi and coauthors and recently reviewed in detail [11], several other nuclear imaging modalities have been proposed for imaging cardiac amyloidosis, such as Tc-aprotinin [12] and I-metaiodobenzylguanidine (MIBG) [13]. Over 25 years ago the uptake of technetium pyrophosphate (then used as a myocardial infarction imaging agent) was described in both AL and TTR amyloidosis, although the sensitivity of the imaging was subject to debate [14–16]. The type of technetium-based isotope was believed to be significant, as Tc-MDP showed little consistency for imaging amyloid cardiomyopathy, despite occasional case reports of cardiac uptake [17]. With the rapid advances in echocardiography and the echocardiographic descriptions of amyloid cardiomyopathy, technetium pyrophosphate cardiac imaging for possible amyloid cardiomyopathy became obsolete, limited to a radiologic curiosity when incidentally seen on a scan performed for other reasons such as for the evaluation of metastatic disease. Echocardiography still remains the mainstay for the initial suspicion/diagnosis of cardiac amyloidosis [1] (and was also a component of the “gold standard” used in this study), and is nowadays often complemented by cardiac MRI which R. H. Falk : S. Dorbala Cardiac Amyloidosis Program, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Pursuing an underdiagnosed disease: a simple imaging test for increasing suspicion of cardiac amyloidosis